Disruption of oncogenic pathways in mucoepidermoid carcinoma: CREB inhibitor 666.15 as a potential therapeutic agent
Authors:
Open Access
- 26 September 2024
- journal article
- research article
- Published by Elsevier in Oral Oncology
- Vol. 159, 107029
Abstract
No abstract availableKeywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2021/10810-6)
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2019/26676-7)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- University of Michigan
This publication has 47 references indexed in Scilit:
- Distribution and Frequency of Salivary Gland Tumours: An International Multicenter StudyHead and Neck Pathology, 2022
- What turns CREB on? And off? And why does it matter?Cellular and Molecular Life Sciences, 2020
- In Vitro Tumorigenic Assay: Colony Forming Assay for Cancer Stem Cells2017
- Role ofCRTC1/MAML2Translocation in the Prognosis and Clinical Outcomes of Mucoepidermoid CarcinomaJAMA Otolaryngology–Head & Neck Surgery, 2016
- Salivary Mucoepidermoid Carcinoma: A Multi-Institutional Review of 76 PatientsHead and Neck Pathology, 2012
- Prospective testing of mucoepidermoid carcinoma for the MAML2 translocation: Clinical ImplicationsThe Laryngoscope, 2012
- Prognostic factors in mucoepidermoid carcinoma of the salivary glandsCancer, 2011
- A new type of MAML2 fusion in mucoepidermoid carcinomaGenes, Chromosomes and Cancer, 2007
- CRTC1/MAML2 fusion transcript in high grade mucoepidermoid carcinomas of salivary and thyroid glands and Warthin's tumors: Implications for histogenesis and biologic behaviorGenes, Chromosomes and Cancer, 2007
- Prognostic Factors in Head and Neck Mucoepidermoid CarcinomaJAMA Otolaryngology–Head & Neck Surgery, 2004